No Data
CCORF Maintains Cybin(CYBN.US) With Buy Rating, Maintains Target Price $86
Optimistic Buy Rating for Cybin: Promising CYB003 Phase 2 Results and Market Potential
HC Wainwright & Co. Reiterates Buy on Cybin, Maintains $190 Price Target
Sector Update: Health Care Stocks Mixed Premarket Monday
Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
No Data
No Data